All you need to know
Carb Blocker Clinical Study
Several clinical studies have been carried out to prove the efficacy and safety of XLS Medical Carb Blocker. The clinical support for XLS Medical Carb Blocker has been well received by the scientific community and as such our clinical study has been peer reviewed and is due to be published in the journal Obesity, the official journal of The Obesity Society.
Our main clinical study took place in in 2011 with 123 volunteers who were classified as overweight or obese. Each volunteer agreed to complete the study in the comfort of their homes and they were given a daily diet plan which was 500 calories less than their daily calorie needs per day and included at least 40% carbohydrate content.
The volunteers were also split into two groups. One group received a daily 3g dose of PhaseLite™ (the active ingredient of XLS Medical Carb Blocker) whilst the other group received a placebo. The volunteers did not know which group they were in but they all took 2 tablets, 3 times a day with liquid immediately before meals for a period of 12 weeks.
After 12 weeks the results clearly showed on average the group who had been taking PhaseLite™ lost 3x more weight than the dieters in the placebo group. It is this difference between the two groups which demonstrates how XLS Medical Carb Blocker can help you lose up to 3x more weight than dieting alone.
XLS Medical Carb Blocker has also been shown to be effective for weight maintenance. From the initial 123 volunteers, 49 volunteers continued to take PhaseLite™ and results show they continued to maintain their initial weight loss.
Carb Blocker Clinical Study Reference: *Grube et al. 2013. Weight Reduction and Maintenance with IQP-PV-101: A 12-Week Randomized Controlled Study with a 24-Week Open Label Period.